STOCK TITAN

Incyte Genomics (INCY) Stock News, May-Jun 2021

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Summary

Incyte Corporation (Nasdaq:INCY) announced that the FDA has extended the review period for its New Drug Application (NDA) for ruxolitinib cream for treating atopic dermatitis by three months to September 21, 2021. This extension allows the FDA to review additional data provided by Incyte, considered a Major Amendment to the NDA. The company remains confident in the cream's potential as a safe treatment option and continues its collaboration with the FDA to expedite its availability to patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
-
Rhea-AI Summary

Incyte announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for treating steroid-refractory chronic graft-versus-host disease (GVHD) in patients aged 12 and older. The new PDUFA target date is September 22, 2021, allowing time for the FDA to review additional data submitted by Incyte. This amendment is considered a Major Amendment, resulting in a three-month extension. Incyte remains confident in the data from the REACH3 trial supporting the sNDA submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
-
Rhea-AI Summary

MorphoSys US Inc. and Incyte announced new three-year follow-up data from the Phase 2 L-MIND study of tafasitamab in combination with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The study included 80 patients and showed an overall response rate (ORR) of 57.5% and a complete response (CR) rate of 40%. The median duration of response (DoR) was 43.9 months with median overall survival (OS) at 33.5 months.

Results were presented at the 2021 ASCO Annual Meeting and indicate potential long-term disease control for difficult-to-treat DLBCL patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
Rhea-AI Summary

Incyte and MorphoSys US Inc. announced new three-year follow-up data from the Phase 2 L-MIND study of tafasitamab (Monjuvi) combined with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Of 81 patients, 80 were evaluated, showing an overall response rate of 57.5% and a complete response rate of 40%. Median progression-free survival was 11.6 months, and overall survival was 33.5 months. Tafasitamab was FDA-approved in July 2020 for DLBCL patients not eligible for autologous stem cell transplant, demonstrating significant long-term efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
Rhea-AI Summary

Eli Lilly and Incyte presented data at the EULAR Congress indicating that OLUMIANT® (baricitinib) 4 mg significantly reduced pain and morning joint stiffness while enhancing physical function at 12 weeks in moderate to severe rheumatoid arthritis patients compared to HUMIRA® (adalimumab) and placebo. The analysis, based on the Phase 3 RA-BEAM study with 1,305 participants, highlighted improved patient-reported outcomes and consistent safety results. OLUMIANT is approved in over 75 countries for RA treatment and recently received approval in Japan for COVID-19 pneumonia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
-
Rhea-AI Summary

Incyte announced its participation in several investor conferences throughout June 2021. Key events include the William Blair 41st Annual Growth Stock Conference on June 3, the BioPharma Sustainability Roundtable’s CEO Investor Forum on June 7, the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, and Guggenheim’s series on June 28. These presentations will be available for live webcast and replay at Investor.Incyte.com.

Incyte is a biopharmaceutical company focused on addressing unmet medical needs through innovative therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
conferences
Rhea-AI Summary

Incyte (Nasdaq: INCY) announced multiple abstracts showcasing data from its oncology portfolio to be presented at the 2021 ASCO Annual Meeting held from June 4-8, 2021. Key highlights include three-year data from the L-MIND study of tafasitamab and results from the OPTIC study of ponatinib. Key abstracts cover various studies including the use of ponatinib in leukemia, tafasitamab for lymphoma, and capmatinib for non-small cell lung cancer. The company remains committed to addressing serious medical needs through innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
none
-
Rhea-AI Summary

Incyte announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program for ruxolitinib cream in patients with vitiligo. Both TRuE-V1 and TRuE-V2 studies met the primary endpoint, showing a significant improvement in facial vitiligo scoring (p0.0001) with 1.5% ruxolitinib cream applied twice daily. Secondary endpoints also showed favorable patient outcomes. The company plans to submit marketing applications to the FDA and EMA in H2 2021. Ruxolitinib cream could become the first approved treatment for vitiligo, addressing a significant unmet medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
-
Rhea-AI Summary

Incyte (Nasdaq:INCY) announced that its oncology portfolio data will be presented at the EHA 2021 Virtual Congress from June 9-17, 2021. Highlights include the first presentation of Phase 2 study data for parsaclisib in autoimmune hemolytic anemia and real-world data on ruxolitinib. Key abstracts cover studies on ponatinib, ruxolitinib, and combination trials with parsaclisib, emphasizing Incyte's commitment to addressing significant unmet medical needs in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Rhea-AI Summary

Incyte and MorphoSys have commenced the pivotal Phase 3 frontMIND trial, dosing the first patient to evaluate a combination treatment of tafasitamab and lenalidomide with R-CHOP for high-risk diffuse large B-cell lymphoma (DLBCL) patients. DLBCL affects about 30,000 individuals annually in the U.S., with a significant unmet need as current treatments yield poor outcomes for high-risk groups. The study aims to enroll 880 patients, focusing on progression-free survival and overall response rates. These efforts follow encouraging preliminary results from previous trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.